ArticleFrontiers in bioengineering and biotechnology2025
Updated transient gene expression protocol in Expi293F cells using PEI.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineering Protein-Based HIV Entry Inhibitors: Advances, Challenges, and Translational Strategies.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transient gene expression (TGE) is commonly used for the rapid production of protein-based therapeutics, including antibodies that require post-translational modifications. We previously published a protocol for efficient and cost-effective TGE of multispecific and multivalent antibodies. Here, we describe an optimized version of this protocol with key improvements in cost, workflow speed, and production capacity. First, the expensive Expi293 expression medium was replaced with BalanCD HEK293 medium, resulting in a substantial decrease in medium-related costs by approximately 90%. The addition of Pluronic F-68 was omitted, as the new medium already contains a similar surfactant. To minimize plasmid DNA usage, salmon sperm DNA was included as filler DNA during transfection, enabling a significant reduction in plasmid DNA input without compromising antibody yield. Second, the harvesting procedure was shortened from 2.5 h to just 15 min by adding the mineral compound diatomaceous earth (Celpure®) to the culture supernatant. This effectively absorbs and sequesters cells and debris, allowing rapid filtration without filter clogging or the previously required 1-h centrifugation step. Finally, we recommend high-flow rate HiScreen Fibro PrismA columns to further accelerate downstream antibody purification. Together, these improvements streamline the TGE workflow in Expi293F cells, enhance scalability, and increase throughput while maintaining efficiency in antibody production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.